Embree Financial Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.31M Sell
1,093
-4
-0.4% -$4.09K 0.13% 102
2026
Q1
$1.01M Buy
1,097
+151
+16% +$153K 0.12% 113
2025
Q4
$1.02M Buy
946
+100
+12% +$95.6K 0.12% 108
2025
Q3
$646K Buy
846
+10
+1% +$7.44K 0.09% 130
2025
Q2
$651K Buy
836
+126
+18% +$97.9K 0.1% 123
2025
Q1
$586K Buy
710
+15
+2% +$12.5K 0.1% 126
2024
Q4
$537K Sell
695
-80
-10% -$66.2K 0.09% 117
2024
Q3
$687K Buy
775
+64
+9% +$57.5K 0.12% 102
2024
Q2
$643K Sell
711
-151
-18% -$121K 0.12% 97
2024
Q1
$671K Buy
862
+178
+26% +$127K 0.13% 95
2023
Q4
$399K Buy
+684
New +$399K 0.08% 126

Other funds holding LLY

Embree Financial Group's LLY Position: Q2 2026 in Review

Embree Financial Group reduced its Eli Lilly (LLY) stake by 0.36% in Q2 2026, selling an estimated $4.09K and leaving 1,093 shares worth $1.31M. The position accounts for 0.13% of the portfolio, ranked #102.

Embree Financial Group first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 841 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Embree Financial Group held 1,093 shares of Eli Lilly worth $1.31M as of Q2 2026.
  • Embree Financial Group sold 4 Eli Lilly shares in Q2 2026, an estimated $4.09K.
  • Eli Lilly made up 0.13% of Embree Financial Group's portfolio in Q2 2026, its #102 holding.
  • Embree Financial Group first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 841 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Embree Financial Group's 13F filing for Q2 2026, filed 15 Jul 2026.